For the quarter ending 2025-09-30, LRMR made $51,286K in revenue. -$47,712K in net income. Net profit margin of -93.03%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 44,931 | 23,368 | ||
| General and administrative | 4,568 | 4,424 | ||
| Total operating expenses | 49,499 | 27,792 | ||
| Loss from operations | -49,499 | -27,792 | ||
| Other income, net | 1,787 | 1,610 | ||
| Net loss | -47,712 | -26,182 | ||
| Earnings per share, basic, total | -0.61 | -0.41 | ||
| Net loss per share, diluted | -0.61 | -0.41 | ||
| Weighted average common shares outstanding, diluted | 78,324,767 | 64,027,892 | ||
| Weighted average number of shares outstanding, basic, total | 78,324,767 | 64,027,892 | ||
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)